Short answer
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Praxis Precision Medicines, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Press release containing the results furnished as Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FDA decisions pending for ulixacaltamide on January 29, 2027 and relutrigine on December 27, 2026, key commercialization catalysts
- Cash and investments $1.3B as of September 30, 2026, supporting operations into 2028 and reducing near-term financing risk
- Third-quarter net loss $94.2M, widening from $73.9M, driven by general and administrative expenses rising to $42.7M
- R&D expense $64.2M, down from $65.8M, while nine-month operating expenses reached $309.7M
- EMERALD topline results expected in fourth quarter 2026, with EMBRAVE3 topline results anticipated in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Praxis Precision Medicines, Inc. 8-K filings
Get the next PRAX 8-K as it lands
Follow PRAX for push alerts, or ask the research agent what this filing means.